Gil M. Labrucherie - Nov 16, 2021 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Signature
Mark A. Wilson, Attorney-in-Fact
Stock symbol
NKTR
Transactions as of
Nov 16, 2021
Transactions value $
-$316,391
Form type
4
Date filed
11/18/2021, 05:06 PM
Previous filing
Dec 20, 2021
Next filing
Dec 20, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NKTR Common Stock Sale -$278K -21.1K -7.53% $13.16 260K Nov 16, 2021 Direct F1, F2, F3
transaction NKTR Common Stock Sale -$38.1K -3K -1.16% $12.69 257K Nov 18, 2021 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 This transaction was executed in multiple trades at prices ranging from $12.84 to $13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
F3 This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
F4 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.